Intellia Plans IPO, Signs Gene-Editing Pact With Regeneron

Intellia Therapeutics, a US-based developer of human medicines based on the gene editing technology CRISPR-Cas9, has filed an IPO prospectus while also announcing a licensing and collaboration agreement with Regeneron Pharmaceuticals.